The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor
Stroke is the second-leading cause of death and the third-leading cause of disability worldwide
Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right
But acquisition charges drag earnings into loss
Leading orthopaedic experts call for equitable insurance coverage to patients for accessing advanced, precision-driven joint replacement technologies
Tamir brings more than 20 years of experience in the medical technology sector
Reshaped by COVID-19, rising test demand, and a shift toward decentralized diagnostics, qPCR has evolved from niche academic use to a core clinical engine
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Pharma and biotech infrastructure firm targets 25–30% growth as Middle East and Africa emerge as key expansion markets
The trials -- ELOWEN-1 and ELOWEN-2 -- are designed to evaluate the drug in people living with lupus who experience active skin manifestations
Subscribe To Our Newsletter & Stay Updated
